ClinicalTrials.gg
TerminatedNCT05065957Updated Nov 4, 2026

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

A Phase 2/3 interventional study of D07001-softgel capsules + Xeloda (or TS-1) and mFOLFOX in Biliary Tract Cancer, sponsored by InnoPharmax Inc.. Terminated at 5 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by InnoPharmax Inc. · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment.

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.
Updated Nov 4, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Biliary Tract Neoplasms with a site in Taiwan — 13 open to participants now, 20 under way, 6 of them phase 3. Biliary Tract Neoplasms · Taiwan.

Enrollment
37th of 40
19 · median 210
Started
2022
with 5 others
Phase 2/3
3 of 41
none open now
Registered
22nd of 41
by date
Lead sponsor
3 of 41
InnoPharmax Inc.

Among the 41 studies in Biliary Tract Neoplasms with a site in Taiwan, this one is the 37th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2022, is one of 3 in phase 2/3, and was the 22nd registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

13 of the 41 studies in Biliary Tract Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Biliary Tract Neoplasms with a site in Taiwan, or all of them as a file.
02

Study summary

The primary objective are:

To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1.

To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

Read the detailed description

This open label, multicenter study will be conducted in 2 stages: a dose-finding stage (Phase IIa) and a dose-expansion stage (Phase IIb/III).

In phase IIa, eligible patients will be assigned to receive oral D07001-softgel on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle (9 doses per cycle) and Xeloda (or TS-1) twice daily on Day 1-14 of a 21-day cycle.

A modified 3+3 dose-finding design method will be applied to identify dose-limiting toxicities (DLTs) and establish the selected dose of D07001-softgel capsules plus Xeloda (or TS-1).

In phase IIb/III,the first 40 subjects (20 subjects per arm) will be randomly allocated in a 1:1 ratio in two arms. Arm A will receive active symptom control (ASC) with the selected dose from dose-finding stage of D07001-softgel capsules and Xeloda (or TS-1), in 21-day cycles. In arm B, subjects will receive ASC with mFOLFOX treatment. After the last subject of first 40 subjects will be completed the visit in the end of treatment, an adaptive interim analysis will be planned to re-estimate the required sample size based on the result of DCR if needed. The sponsor team will determine whether the study will be continued or stopped for futility.

If the study continues to proceed, the total subject number will be based on the decision from the results of interim study. The rest of subjects will be randomized to receive the combination of study drug or active-control drug with the same allocation in two arms. Both groups will continue the therapy until disease progression, withdrawn consent, or when another treatment discontinuation criterion is met.

03

Conditions studied

  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 18 years or older at screening (aged 20 years or older in Taiwan)
  2. Histopathological or cytologic diagnosis of unresectable or locally advanced BTC (cholangiocarcinoma, gallbladder cancer or ampullary carcinoma)
  3. Subject must have failed from gemcitabine and cisplatin-based chemotherapy
  4. (ECOG) Performance Status (PS) of 0-1
  5. is >12 weeks
  6. Adequate bone marrow function, demonstrated by:

    1. (ANC) ≥1,500 cell/mm3
    2. count ≥ 100,000 cells/mm3
    3. ≥ 9 g/dL
  7. Adequate liver function, demonstrated by:

    1. (AST) and alanine transaminase (ALT) ≤2.5 x (ULN), or ≤5.0 x ULN in the case of liver metastases
    2. Total ≤1.5 x ULN
    3. Albumin ≥3.0 g/dL
    4. (INR) \<1.5
  8. Adequate renal function, demonstrated by:

    1. Serum creatinine ≤1.5 x ULN
    2. ≥ 50mL/min calculated by Cockcroft-Gault formula or ≥ 50mL/min/1.73m2 by 2021 CKD-EPI Creatinine Equation
  9. A negative serum pregnancy test at screening and is not breastfeeding in woman of
  10. Women of childbearing potential or male subjects must use a medically acceptable form of as 2 barrier methods (e.g., combination of condom, diaphragm, or intrauterine device), hormonal contraception (estrogen or progesterone agents) or 1 barrier method in combination with spermicide. Birth control is required 1 month prior to screening, for the duration of their study participation, and for 1 month after the end of the study; female partners of male subjects must adhere to the same birth control methods.
  11. Provision of a signed and dated written Form (ICF) prior to any study specific procedures
  12. Subject is willing to comply with protocol-required visit schedule and visit requirements
  13. No more than 60 days have elapsed between completion of the prior line of chemotherapy or CCRT and enrollment
  14. Subject has not received other chemotherapy since first-line treatment

Exclusion criteria

Exclusion Criteria:

  1. Have prior chemotherapy regimen other than gemcitabine and cisplatin-based therapy for unresectable or locally advanced BTC Note: prior fluoropyrimidine base (including capecitabine, carmofur (HCFU), doxifluridine, fluorouracil (5-FU), and tegafur) chemotherapy (including fluoropyrimidine monotherapy or combination therapy) are allowed as postsurgical therapy.
  2. Diagnosis of active other than BTC within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent
  3. Prior discontinuation of gemcitabine because of pulmonary or hepatic toxicity or hemolytic uremic syndrome (HUS) or , allergic reaction, or intolerance
  4. Known or suspected hypersensitivity to capecitabine, tegafur, gimeracil, oteracil potassium, oxaliplatin or other platinum compounds, leucovorin products, folic acid or folinic acid, 5-fluorouracil or their .
  5. Prior discontinuation of fluoropyrimidine because of any unexpected or severe reaction.
  6. Treatment with brivudine, sorivudine, or its chemically-related analogs ≤ 28 days prior to the date of enrollment.
  7. Under flucytosine treatment.
  8. Residual toxicity from prior chemotherapy or CCRT that is Grade ≥2 (residual Grade 2 neuropathy and alopecia are permitted)
  9. Any GI disorder which would significantly impede absorption of an oral agent
  10. Known brain or
  11. Major surgery or definitive ablation-intent (excluding palliative radiotherapy for bone metastasis) radiation therapy within the past 28 days
  12. Any active disease or condition that would not permit compliance with the protocol
  13. cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, or [NYHA] Grade 2 or greater), or uncontrolled serious cardiac arrhythmia
  14. Have documented cerebrovascular disease. Subjects with the disease may be excluded, but if the investigator assesses that they are asymptomatic or well controlled could be enrolled.
  15. Have a seizure disorder not controlled on medication (based on decision of Investigator)
  16. Received an agent within 28 days of enrollment
  17. Have an uncontrolled active viral, bacterial, or systemic fungal infection
  18. Known (HIV) infection
  19. Have (hepatitis B surface antigen) positive with HBV-DNA ≥2000 copies/ml and/or anti- antibody (HCV) positive with HCV-RNA positive.
  20. Received yellow fever vaccine or other (s) within the 4 weeks prior to screening
  21. History of drug or alcohol abuse within last year
  22. Have any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in, and compliance with, a clinical trial
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Phase IIa:Dose-Finding Stage

    Level -5: 20 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1). Level -4: 40 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1). Level -3: 60 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1). Level -2: 80 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1). Level -1 (starting dose): 100 mg D07001-softgel capsules plus 625 mg/m\^2 Xeloda (or 20/30/40 mg TS-1). Level 1: 100 mg D07001-softgel capsules plus 800 mg/m\^2 Xeloda (or 30/40/50 mg TS-1). Level 2: 100 mg D07001-softgel capsules plus 1000 mg/m\^2 Xeloda (or 40/50/60 mg TS-1).

    Drug: D07001-softgel capsules + Xeloda (or TS-1)

  • Active comparator
    Phase IIb/III: Dose Expansion Stage

    ASC+ D07001-softgel capsules plus Xeloda (or TS-1) ASC+mFOLFOX (5-FU+Oxalipatin+folinic acid)

    Drug: D07001-softgel capsules + Xeloda (or TS-1) · Drug: mFOLFOX

Interventions

  • DrugD07001-softgel capsules + Xeloda (or TS-1)

    D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle). Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

    Also known as: Treatment group

  • DrugmFOLFOX

    intravenous infusion on Day 1 for 14-day cycle

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)/ serious adverse event (SAEs)

    AEs will be assessed via the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

    Time frame: From date of informed consent to 30-day follow-up visit for each subject

  2. To assess disease control rate (DCR)

    To assess DCR, the percentage of treatment patients who achieved CR, PR, or SD.

    Time frame: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

Secondary outcomes

  1. Phase IIa and IIb: Pharmacokinetics (PK) of gemcitabine (dFdC), difluorodeoxyuridine (dFdU), capecitabine, 5-FU, Tegafur, Gimeracil, and Oteracil potassium

    PK parameters (Peak Plasma Concentration (Cmax)) of gemcitabine and Xeloda or TS-1 will be evaluated

    Time frame: Cycle 1 Days 1, 8, and 12 (each cycle is 21 days)

  2. Quality of life (QOL) will be assessed using the EORTC questionnaires

    To access healthrelated quality of life of cancer patients participating in clinical trial.

    Time frame: Cycle 1 Days 1, and date of withdraw the study (assessed up to 24 months) for each subject (each cycle is 21 days)

  3. To assess Progression-free survival (PFS)

    To assess PFS, the time from treatment assignment/randomization until objective tumor progression or death

    Time frame: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

  4. To assess Objective response rate (ORR)

    To assess ORR, the proportion of treated patients who achieved a BOR of CR or PR.

    Time frame: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

  5. To assess overall survival (OS)

    To assess OS, the time from treatment assignment/randomization until death from any case

    Time frame: The survival follow-ups will follow every 6 weeks from date of discontinued study drug for up to 24 months till the death of the subject or closure of the study.

07

Study locations

5 sites
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • China Medical University Hospital
    Taichung, 404, Taiwan
  • National Taiwan University Cancer Center
    Taipei, Taiwan
  • National Taiwan University Hospotal
    Taipei, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taiwan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2022 to primary completion in Jul 2025, 40 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jul 2026 → Jul 2025 and completion Dec 2026 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2021
First posted
Oct 4, 2021
StartActual
Mar 29, 2022
Primary completionActual
Jul 31, 2025was Jul 2026
CompletionActual
Jul 31, 2025was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment.
changed Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
Show 1 removed
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
Nov 4, 2026
Primary completion
Jul 2026→Jul 31, 2025 (actual)
Nov 4, 2026
Study completion
Dec 2026→Jul 31, 2025 (actual)
Nov 4, 2026
Enrollment
180 (estimated)→19 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Terminated
    Why stopped Dose-finding stage has been completed, and dose-expanding stage was not conducted due to design amendment.
    1 site added, 1 site removed
    Show site
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
    Show 1 removed
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung, Taiwan
    Primary completion Jul 2026→Jul 31, 2025 (now actual)
    Study completion Dec 2026→Jul 31, 2025 (now actual)
    Enrollment 180 (estimated)→19 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05065957
Lead sponsor
InnoPharmax Inc.
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Mar 29, 2022
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Last update
Nov 4, 2026

Study contacts

Li-Tzong Chen, Ph.D
principal investigator · National Institute of Cancer Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion